Video summary

Microgravity: Developing Drugs in Space #InOrbit #Podcast

Main summary

Key takeaways

Science and Nature

Scientific Concepts / Nature Phenomena Presented

Microgravity and Weightlessness

  • Microgravity ≠ absence of gravity. It refers to the reduced “effect” of gravity when in free fall.
  • On Earth, gravity is continuous, and organisms have evolved under it.
  • On the International Space Station (ISS), spacecraft are in orbit and free-falling, creating weightlessness (often described as about a millionth of g).
  • Parabolic flight can briefly produce similar free-fall/weightlessness conditions.

How Microgravity Changes Physical / Biological Processes

Microgravity reduces or removes gravity-driven effects, leading to changes such as:

  • Reduced/absent sedimentation (gravity-driven settling)
  • Reduced/absent convection (buoyancy-driven fluid motion)
  • Surface tension becomes more prominent, encouraging more spherical and ordered structures

Impacts on living systems include:

  • Bone mass loss
  • Muscle structure changes
  • Effects on heart function and vision

A specific bone loss rate mentioned:

  • ~1–1.5% per month in microgravity

Crystallization for Structural Biology and Drug Design

Drug design often depends on determining protein structure, commonly using X-ray crystallography. However, crystals are a key bottleneck, because structure determination requires crystalline samples.

Why microgravity helps:

  • Improves crystal quality
  • Enables:
    • slower growth/segmentation
    • more ordered structures
    • larger crystals, improving structural data

Earth vs. space comparison:

  • On Earth, gravity/convection/sedimentation can disrupt crystal growth and reduce crystal quality.

Alternative Structure-Determination Approaches (Complementary to Crystallography)

  • Cryo-electron microscopy (cryo-EM): structural information without requiring crystals in many cases.
  • AI / in silico protein structure prediction: computational derivation of protein structures (not a complete replacement yet).

Disease / Drug-Discovery Applications Discussed

  • HIV reverse transcriptase
    • Structure studies supported development of non-nucleoside reverse transcriptase inhibitors (NNRTIs).
  • Cancer biology
    • Microgravity research can affect gene expression; some genes may be unexpressed in microgravity.
    • Example area mentioned: interferon-related development.
  • Osteoporosis and bone loss
    • Example therapeutic class: alendronate (bisphosphonate), with established benefit-risk on Earth and evidence of benefit in astronauts.
    • Regulatory gap: difficulty approving treatments specifically for bone loss in space.
  • Immunotherapy / oncology drug example
    • Pembrolizumab (Keytruda) was discussed regarding space-enabled development of subcutaneous formulations (rather than IV).

Pharmaceutical Formulation and Route of Administration

Microgravity-enabled R&D could support more patient-friendly drug formats, especially:

  • Subcutaneous injections rather than intravenous administration

Manufacturing / Commercialization Barriers

Key constraints mentioned:

  • Reliability of running experiments in space
  • Cost (launch and operating costs; “tens of thousands per kilo” mentioned)
  • Time scale / speed of iteration in space-based programs
  • Regulatory challenges
  • Limited astronaut time
  • Need for automation / robotics
  • Need to miniaturize labs/manufacturing systems due to mass and cost

3D Bioprinting Concept (Future-Oriented)

Potential future uses include printing artificial skin, small organs, or cartilage-like structures in space on demand. The rationale given is that microgravity may:

  • improve product quality
  • enable better organization

Methods / Workflows (Explicit or Implied)

Structural Drug Discovery Pipeline (Referenced)

A workflow described as:

  1. Identify a disease target protein
  2. Obtain its protein structure
  3. Design drugs (e.g., inhibitors)

Core Earth approach:

  • X-ray crystallography (requires protein crystals)

Complementary / alternative approaches:

  • cryo-EM
  • AI-based in silico structure prediction

Use-case concept:

  • Combine Earth + microgravity + computational + cryo-EM to reduce bottlenecks.

Space Drug R&D “Commercialization Value Chain” (Roadmap Framing)

The process was framed as stages from:

  • drug discovery → development → commercialization

Microgravity should be used only if it:

  • improves outcomes
  • helps generate ROI
  • derisks development

Other roadmap elements mentioned:

  • Align with regulators, suppliers, and investors
  • Create specific use cases to avoid becoming “academic curiosity”

Researchers / Organizations / Sources Featured (Named)

  • Dallas Campbell (host)
  • Martin Bradock (founder/director, Genix Eye Consulting)
  • William Burch (Strategic account director for space, Satellite Applications Catapult)
  • University of Oxford
  • MRC Radiobiology Unit (Medical Research Council radiobiology unit referenced)
  • GlaxoSmithKline
  • Astro- or “Astroenica” (company referenced; subtitles show “Astroenica/Astroenica”)
  • Eli Lilly
  • Merc / Merck (subtitles: “Merc”)
  • VA / V (space company referenced; subtitles imply missions/development context including Ritonavir)
  • Axiom Space
  • Fast / “Fast but” (subtitles unclear; mentioned as platform/player)
  • Space Forge (UK; semiconductors mentioned)
  • Exploration company out of Europe (free-flyer plans mentioned; specific name unclear in subtitles)
  • Redwire Space
  • China and America (as countries with increased space access)
  • UKRI (UK Research and Innovation)
  • ESA / European organizations (implied, not clearly named)
  • Satellite Applications Catapult
  • Space Forge (funding announcement referenced)
  • ISS (International Space Station)
  • National / regulatory bodies (not explicitly named)
  • Astronaut center in Cologne (facility referenced; exact name not fully given)

Note: NASA/ESA terms were not broadly explicit beyond ISS, but the International Space Station is explicitly named.

Notable Drug Examples Mentioned

  • Alendronate (bisphosphonate) for osteoporosis/bone loss
  • Ritonavir (HIV drug referenced as developed in space)
  • Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
  • Pembrolizumab (Keytruda) (subcutaneous formulation development referenced)
  • “Katruda” (subtitles; interpreted as pembrolizumab)

Original video